Metastasis-free chemotherapy for intestinal mucinous adenocarcinoma is generally not recommended to use Bevacizumab, which needs to be determined by the doctor according to the patient’s specific condition and physical condition. Bevacizumab is a recombinant monoclonal IgG1 antibody, which plays an anti-cancer role by inhibiting the biological activity of vascular endothelial growth factor, and is mainly used in various types of metastatic cancers. Bevacizumab is actually an anti-tumor angiogenesis targeted drug, and colon mucinous adenocarcinoma has not metastasized, usually do not need to use targeted therapy. Therefore, bevacizumab is usually not suitable for colon mucinous adenocarcinoma without metastasis, but each patient’s specific condition is different, and the doctor needs to choose the appropriate treatment plan after evaluation according to individual conditions. Mucinous adenocarcinoma of colon is a kind of malignant tumor of digestive system, which is easy to spread and metastasize. In the early stage of the disease without metastasis, it can be treated by surgical resection and lymphatic cleansing. If metastasis has occurred in the middle or late stage of the disease, it needs to be controlled by radiotherapy, chemotherapy, targeted therapy and other comprehensive methods. After being diagnosed with mucinous adenocarcinoma of colon, patients should actively cooperate with doctors for treatment, and consult doctors for any abnormalities or anything they don’t understand during the treatment period, so as to eliminate the psychological burden.